AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27283295 — intervention group
Group type: COMPARATOR
Intervention: NHIS subgroup based on Internet use and cessation behavior (control group)
Number of subjects: 5290
Study 24660837 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral n‐3 fatty acids (2 ml/kg/day of a lipid emulsion containing highly refined fish oil for 7 days)
Number of subjects: 50
Study 24660837 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 50
Study 24660837 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral n‐3 fatty acids
Number of subjects: 50
Study 22681705 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 50
Study 22681705 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 50
Study 19083199 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 FORTE (twice a day)
Number of subjects: 259
Study 19083199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose-based)
Number of subjects: 259
Study 19083199 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 FORTE
Number of subjects: 259
Study 19083199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 17720993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17720993 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Urocortin 2 (25 microg)
Number of subjects: 8
Study 17720993 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Urocortin 2 (100 microg)
Number of subjects: 8
Study 17720993 — intervention group
Group type: EXPERIMENTAL
Intervention: Urocortin 2 (100 microg)
Number of subjects: 8
Study 16633764 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative flurbiprofen axetil, 1 mg x kg(‐1)
Number of subjects: 36
Study 14514944 — intervention group
Group type: EXPERIMENTAL
Intervention: ACBT + NIV
Number of subjects: 26
Study 14514944 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ACBT)
Number of subjects: 26
Study 10789839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacalcitol 0.4 microg/g ointment
Number of subjects: 25
Study 10789839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacalcitol 4 microg/g ointment
Number of subjects: 25
Study 10789839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacalcitol 40 microg/g ointment
Number of subjects: 25
Study 10789839 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 25
Study 8695107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 micrograms administered through a spinal needle
Number of subjects: 23
Study 8695107 — intervention group
Group type: COMPARATOR
Intervention: No intravenous (i.v.) fluid
Number of subjects: 23
Study 1832500 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 (a new oral biological response modifier)
Number of subjects: 39
Study 1832500 — intervention group
Group type: COMPARATOR
Intervention: Oral washes (control group)
Number of subjects: 39
Study 6350411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg single dose)
Number of subjects: 11
Study 6350411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg t.i.d. for 4 days)
Number of subjects: 11
Study 6350411 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (4 days)
Number of subjects: 11
Study 31718628 — intervention group
Group type: EXPERIMENTAL
Intervention: Loudspeaker announcements regarding malaria care and prevention practices
Number of subjects: 270
Study 31718628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no loudspeaker announcements)
Number of subjects: 270
Study 30442234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU per week)
Number of subjects: 100
Study 30442234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26681392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (anti-VEGF drugs)
Number of subjects: 1183
Study 25561817 — intervention group
Group type: COMPARATOR
Intervention: MMC group (36 patients)
Number of subjects: 144
Study 25561817 — intervention group
Group type: EXPERIMENTAL
Intervention: TQD group (72 patients)
Number of subjects: 144
Study 25561817 — intervention group
Group type: EXPERIMENTAL
Intervention: TTK group (36 patients)
Number of subjects: 144
Study 22313454 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic central lymph node dissection
Number of subjects: 5840
Study 22313454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic central lymph node dissection)
Number of subjects: 5840
Study 19160408 — intervention group
Group type: EXPERIMENTAL
Intervention: Two applications of Mitomycin-C (MMC) (0.5 mg/mL)
Number of subjects: 26
Study 19160408 — intervention group
Group type: COMPARATOR
Intervention: One application of Mitomycin-C (MMC) (0.5 mg/mL)
Number of subjects: 26
Study 17953883 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 0
Study 16385651 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (2 mL, 50 mg)
Number of subjects: 90
Study 16385651 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 mL)
Number of subjects: 90
Study 12019581 — intervention group
Group type: EXPERIMENTAL
Intervention: Good dynamic trunk extensor performance
Number of subjects: 535
Study 12019581 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 535
Study 10543285 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 27417A (20 mg, orally)
Number of subjects: 12
Study 10543285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8520443 — intervention group
Group type: EXPERIMENTAL
Intervention: AQL (disease-specific quality of life instrument)
Number of subjects: 32
Study 8520443 — intervention group
Group type: COMPARATOR
Intervention: SIP (generic quality of life instrument)
Number of subjects: 32
Study 2182288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 55
Study 2182288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (longer treatment)
Number of subjects: 55
Study 2182288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 7404090 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged glucagon infusion
Number of subjects: 17
Study 7404090 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 17
Study 30469089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 392
Study 30469089 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Care Management (SCM)
Number of subjects: 392
Study 30469089 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 392
Study 27806191 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acebilustat
Number of subjects: 17
Study 27806191 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebilustat (50 mg and 100 mg)
Number of subjects: 17
Study 27806191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25022541 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 2356
Study 25022541 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 2356
Study 25022541 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2356
Study 24057341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban maintenance infusion for 24 hours
Number of subjects: 84
Study 24057341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban maintenance infusion for 48 hours
Number of subjects: 84
Study 24057341 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 21477940 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent carboplatin/paclitaxel with 74 Gy 3D-CRT
Number of subjects: 0
Study 21477940 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent gemcitabine with 74 Gy 3D-CRT
Number of subjects: 0
Study 21477940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (N3 disease and V20 >38%)
Number of subjects: 0
Study 21477940 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related pulmonary toxicity
Number of subjects: 0
Study 19039248 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 plus PLD 30 mg/m(2) every 3 weeks for 6 cycles
Number of subjects: 50
Study 19039248 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin AUC 5 plus paclitaxel 175 mg/m(2) every 3 weeks for 6 cycles
Number of subjects: 50
Study 17460368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 25
Study 17460368 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500-750 mg/day
Number of subjects: 25
Study 17460368 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25
Study 15314865 — intervention group
Group type: EXPERIMENTAL
Intervention: Perftoran (PF)
Number of subjects: 74
Study 11723588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0
Study 11723588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9684138 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative transarterial infusion chemotherapy (PTIC)
Number of subjects: 38
Study 9684138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 38
Study 7889228 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover designs with three or more treatment periods
Number of subjects: 0
Study 7889228 — intervention group
Group type: EXPERIMENTAL
Intervention: Interposing sufficiently long 'washout' periods between successive treatments
Number of subjects: 0
Study 7889228 — intervention group
Group type: EXPERIMENTAL
Intervention: Current model for crossover trials
Number of subjects: 0
Study 2904826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol 50 mg
Number of subjects: 9
Study 2904826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol 100 mg
Number of subjects: 9
Study 2904826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31021833 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐pancreatitis diabetes mellitus (PPDM)
Number of subjects: 959
Study 31021833 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 959
Study 26496368 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 80
Study 26496368 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg/kg
Number of subjects: 80
Study 23095990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (Pico)
Number of subjects: 634
Study 23095990 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 634
Study 23095990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 634
Study 23095990 — intervention group
Group type: COMPARATOR
Intervention: Overall tolerability
Number of subjects: 634
Study 22007013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic PMS (0.45% saline)
Number of subjects: 258
Study 22007013 — intervention group
Group type: COMPARATOR
Intervention: Isotonic PMS (0.9% saline)
Number of subjects: 258
Study 18091334 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy plus carboplatin 100 mg/m intravenously once weekly during radiation (arm B)
Number of subjects: 72
Study 18091334 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy alone (arm A)
Number of subjects: 72
Study 16110522 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg/d)
Number of subjects: 20
Study 16110522 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 14533615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe alone or added to existing statin therapy
Number of subjects: 0
Study 14533615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe alone or combined with a statin
Number of subjects: 0
Study 14618039 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI right atrial pacing
Number of subjects: 0
Study 14618039 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 0
Study 14618039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bachmann's bundle pacing
Number of subjects: 0
Study 14618039 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered mode pacing
Number of subjects: 0
Study 14618039 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive algorithms
Number of subjects: 0
Study 14618039 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant beta-blocker use
Number of subjects: 0
Study 10451163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0, 1, and 6 months vaccination schedule
Number of subjects: 800
Study 10451163 — intervention group
Group type: COMPARATOR
Intervention: 0, 1, and 12 months vaccination schedule
Number of subjects: 800
Study 9620063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 20
Study 9620063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2565093 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 93
Study 2565093 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 93
Study 2565093 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine and Ranitidine
Number of subjects: 93
Study 2565093 — intervention group
Group type: COMPARATOR
Intervention: Other groups (not specified)
Number of subjects: 93
Study 941865 — intervention group
Group type: EXPERIMENTAL
Intervention: Three levels of nitrogen intake; specific dosages not mentioned; duration of study not specified.
Number of subjects: 0
Study 30325889 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual SMT
Number of subjects: 37
Study 30325889 — intervention group
Group type: COMPARATOR
Intervention: Sham SMT
Number of subjects: 37
Study 27497847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue group (pLVAD insertion due to hemodynamic collapse)
Number of subjects: 93
Study 27497847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive group (pre-ablation pLVAD insertion)
Number of subjects: 93
Study 27497847 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pLVAD group (no pLVAD insertion)
Number of subjects: 93
Study 27497847 — intervention group
Group type: COMPARATOR
Intervention: Pre-emptive group
Number of subjects: 93
Study 27497847 — intervention group
Group type: COMPARATOR
Intervention: Non-pLVAD group
Number of subjects: 93
Study 25665612 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection (50 mL added with 100 mL of 0.9% sodium chloride injection, twice a day for 5 days)
Number of subjects: 66
Study 25665612 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 66
Study 22951334 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary medication as the first choice intervention
Number of subjects: 0
Study 22951334 — intervention group
Group type: COMPARATOR
Intervention: Seclusion as the first choice intervention
Number of subjects: 0
Study 22951334 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary medication
Number of subjects: 0
Study 22951334 — intervention group
Group type: COMPARATOR
Intervention: Seclusion
Number of subjects: 0
Study 21353220 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal education and support program (one‐to‐one educational session and follow‐up phone calls at two months and four months postpartum)
Number of subjects: 90
Study 21353220 — intervention group
Group type: COMPARATOR
Intervention: Routine postnatal care (control group)
Number of subjects: 90
Study 21353220 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal education and support program
Number of subjects: 90
Study 18838271 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with three different visual distortion lenses
Number of subjects: 0
Study 18838271 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a single pair of visual distortion lenses
Number of subjects: 0
Study 18838271 — intervention group
Group type: COMPARATOR
Intervention: Sham lenses
Number of subjects: 0
Study 18838271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic balance training
Number of subjects: 0
Study 18065596 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit intake (approximately 5.7 ps/d)
Number of subjects: 32070
Study 18065596 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of deep‐yellow vegetables, dark‐green vegetables, onions and garlic
Number of subjects: 32070
Study 18065596 — intervention group
Group type: COMPARATOR
Intervention: Total vegetable intake
Number of subjects: 32070
Study 14751925 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic blood transfusion
Number of subjects: 130
Study 14751925 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 130
Study 14751925 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated TCD testing
Number of subjects: 130
Study 11405507 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 523
Study 11405507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 9595926 — intervention group
Group type: EXPERIMENTAL
Intervention: SQA (quaternary ammonium antimicrobial compounds)
Number of subjects: 110
Study 9595926 — intervention group
Group type: COMPARATOR
Intervention: CL (clindamycin 2% intravaginal cream)
Number of subjects: 110
Study 9595926 — intervention group
Group type: EXPERIMENTAL
Intervention: SQA
Number of subjects: 110
Study 9595926 — intervention group
Group type: COMPARATOR
Intervention: CL
Number of subjects: 110
Study 8129762 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 208
Study 8129762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 208
Study 8129762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 3041876 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminar flow air cleaner bed attachment (in use)
Number of subjects: 13
Study 3041876 — intervention group
Group type: COMPARATOR
Intervention: Non-use of laminar flow air cleaner bed attachment
Number of subjects: 13
Study 31415468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-Avoidance Beliefs Questionnaire (FABQ)
Number of subjects: 722
Study 31415468 — intervention group
Group type: EXPERIMENTAL
Intervention: Single items of the FABQ
Number of subjects: 722
Study 31415468 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ with added item 'I should not do my regular work with my present pain'
Number of subjects: 722
Study 31099860 — intervention group
Group type: COMPARATOR
Intervention: No computerized cognitive training
Number of subjects: 272
Study 31099860 — intervention group
Group type: COMPARATOR
Intervention: Wellness education
Number of subjects: 272
Study 31099860 — intervention group
Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 272
Study 28109258 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (3.33×10^4 U, n=68)
Number of subjects: 138
Study 28109258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=70)
Number of subjects: 138
Study 28109258 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (3.33×10^4 U)
Number of subjects: 138
Study 28109258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 25499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 848
Study 25499871 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 848
Study 25499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding (overall)
Number of subjects: 848
Study 25499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage (ICH)
Number of subjects: 848
Study 25499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-intracranial hemorrhage (non-ICH)
Number of subjects: 848
Study 25499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Major non-ICH bleeding
Number of subjects: 848
Study 25499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke or MI following ICH
Number of subjects: 848
Study 25499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of major bleeds
Number of subjects: 848
Study 23815103 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP nasal aerosol 320 µg/day
Number of subjects: 0
Study 23815103 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP nasal aerosol 80 µg and 160 µg
Number of subjects: 0
Study 23815103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21829138 — intervention group
Group type: EXPERIMENTAL
Intervention: rcp45 vaccine (2 intranasal doses administered 4 to 10 weeks apart)
Number of subjects: 45
Study 21829138 — intervention group
Group type: EXPERIMENTAL
Intervention: rcp45 vaccine (2nd dose)
Number of subjects: 45
Study 21829138 — intervention group
Group type: COMPARATOR
Intervention: cp45 vaccine (biologically derived)
Number of subjects: 45
Study 21829138 — intervention group
Group type: EXPERIMENTAL
Intervention: rcp45 vaccine
Number of subjects: 45
Study 19468225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5, 7.5, or 10 mg b.i.d. for 3 or 4 months
Number of subjects: 2425
Study 16900817 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations (Clearfil AP-X)
Number of subjects: 94
Study 16900817 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite restorations (Estenia)
Number of subjects: 94
Study 16900817 — intervention group
Group type: COMPARATOR
Intervention: Indirect technique
Number of subjects: 94
Study 16900817 — intervention group
Group type: COMPARATOR
Intervention: Direct technique
Number of subjects: 94
Study 14757687 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin at 2.5 U/h
Number of subjects: 32
Study 14757687 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and potassium (C)
Number of subjects: 32
Study 11162694 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed strain-gauge plethysmograph (CSGP) in Phase 1
Number of subjects: 322
Study 11162694 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed strain-gauge plethysmograph (CSGP) using a modified protocol in Phase 2
Number of subjects: 322